Improving oral oncolytic education in a safety-net outpatient hematology-oncology practice. Read more about Improving oral oncolytic education in a safety-net outpatient hematology-oncology practice.
Predictors of high financial distress in a national, multiethnic sample of patients with cancer. Read more about Predictors of high financial distress in a national, multiethnic sample of patients with cancer.
Evaluating changes in “good safety monitoring” for cancer clinical trial participants during the COVID-19 pandemic. Read more about Evaluating changes in “good safety monitoring” for cancer clinical trial participants during the COVID-19 pandemic.
The marginal diagnostic benefit of pancreatic cancer molecular profiling after germline testing. Read more about The marginal diagnostic benefit of pancreatic cancer molecular profiling after germline testing.
Rate of skeletal-related events (SREs) for abiraterone acetate (AA) versus enzalutamide (ENZ) in prostate cancer: A population-based study using the SEER-Medicare database. Read more about Rate of skeletal-related events (SREs) for abiraterone acetate (AA) versus enzalutamide (ENZ) in prostate cancer: A population-based study using the SEER-Medicare database.
Patterns in cancer management changes for patients with COVID-19 in northern California. Read more about Patterns in cancer management changes for patients with COVID-19 in northern California.
Immunogenic priming with 177 Lu-PSMA-617 plus pembrolizumab in metastatic castration resistant prostate cancer (mCRPC): A phase 1b study. Read more about Immunogenic priming with 177 Lu-PSMA-617 plus pembrolizumab in metastatic castration resistant prostate cancer (mCRPC): A phase 1b study.
Phase II trial of olaparib in combination with ceralasertib in patients with recurrent osteosarcoma. Read more about Phase II trial of olaparib in combination with ceralasertib in patients with recurrent osteosarcoma.
Phase I study of the aurora kinase A inhibitor alisertib in combination with osimertinib in EGFR-mutant lung cancer. Read more about Phase I study of the aurora kinase A inhibitor alisertib in combination with osimertinib in EGFR-mutant lung cancer.
Phase 1 first-in-human study of irreversible FLT3 inhibitor FF-10101-01 in relapsed or refractory acute myeloid leukemia. Read more about Phase 1 first-in-human study of irreversible FLT3 inhibitor FF-10101-01 in relapsed or refractory acute myeloid leukemia.
